)
Visual
test
Syndax Pharmaceuticals
Syndax Pharmaceuticals (SNDX) investor relations material
Syndax Pharmaceuticals 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary12 Jan, 2026
Key Achievements and Financial Performance
Transitioned to a commercial-stage oncology company with two first-in-class drugs and three FDA approvals in 14 months.
Reported $44M in Q4 and $125M in full-year 2025 revenue for Revuforj, with ~38% quarter-over-quarter growth and 1,150 prescriptions in Q4.
Niktimvo generated $56M in Q4 and $152M in full-year 2025 revenue, annualizing at over $200M.
Maintains $400M on the balance sheet and a preliminary year-end 2025 cash position of $394M, supporting ongoing growth.
On track for profitability, driven by strong product launches and expanding market opportunities.
Product Highlights and Market Opportunities
Revuforj is the first and only menin inhibitor approved for multiple acute leukemia subtypes, targeting a $5B+ market.
Demonstrates unmatched efficacy, broad coverage (AML, ALL, adult, pediatric), and strong tolerability, with flexible dosing.
Achieved 50% market penetration in KMT2A, with plans to reach up to 90% over time.
Niktimvo is the first CSF1R inhibitor approved for chronic GVHD, addressing a $2B+ market and expanding into IPF.
High patient retention: 70-80% of Niktimvo patients remain on therapy after 11 months.
Clinical Development and Future Growth
Revuforj clinical program includes pivotal trials in front-line settings and maintenance, aiming for accelerated and full approvals.
Niktimvo is being studied in combination and earlier lines for GVHD, with phase 2 and pivotal trial readouts expected in 2027-2028.
IPF trial (MaxPhier) for Niktimvo is underway, with top-line data expected in H2 2026.
Ongoing data generation and new trials (e.g., RAVEN, myelofibrosis) to expand indications and support global registrations.
Focused on publishing and presenting industry-leading data to drive adoption and value.
Revuforj: Detail the RAVEN trial's strategic value
Niktimvo IPF: Mechanistic confidence and FVC win
Revuforj KMT2A penetration vs. NPM1 guidance
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 443060
Operating profit rose 28.9% in 2025, with strong core business and digital segment growth. - GM
Disciplined transformation, resilient cash flow, and software growth drive a strong outlook. - BTBT
Transitioned to a strategic asset model centered on ETH staking and AI infrastructure growth. - COR
Q1 FY2026 revenue up 5.5% to $85.9B; adjusted EPS rose 9.4% to $4.08. - STC
Scalable, high-margin IT communications provider for SMBs with strong recurring revenue and growth momentum. - APAM
AUM hit $180B, strong returns and Grandview deal drove growth despite equity outflows. - PSX
Q4 2025 earnings hit $2.9B, with record refining yields and strong portfolio transformation. - ARCC
FY 2025 delivered $2.01 Core EPS, $1.86 net income/share, and a $0.48 Q1 2026 dividend. - HMN
Record core earnings, 12.4% ROE, and 10% EPS growth guidance for 2026. - AFG
Record underwriting profit, strong ROE, and over $700M returned to shareholders in 2025.
Next Syndax Pharmaceuticals earnings date
Q4 20253 Mar, 2026
Syndax Pharmaceuticals
Next Syndax Pharmaceuticals earnings date
Q4 20253 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Syndax Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for cancer. The company's lead programs target immune pathways and tumor microenvironments to enhance the body’s ability to fight cancer. Syndax's pipeline includes treatments for both solid tumors and hematologic cancers, aiming to address unmet medical needs by improving outcomes for cancer patients through novel combination therapies. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage